Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type

2021 ◽  
Vol 69 (4) ◽  
pp. 103313
Author(s):  
Lorenzo Lazzari ◽  
Francesca Farina ◽  
Maria Teresa Lupo Stanghellini ◽  
Simona Piemontese ◽  
Sarah Marktel ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
The Central Nervous System ◽  
Killer T Cell

Primary intravascular natural killer/T cell lymphoma of the central nervous system

2014 ◽  
Vol 56 (4) ◽  
pp. 1154-1156 ◽  
Author(s):  
Jianlan Xie ◽  
Xiaoge Zhou ◽  
Xiaojing Zhang ◽  
Yuanyuan Zheng ◽  
Bing Yue
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Natural Killer T Cell ◽  
The Central Nervous System ◽  
Killer T Cell ◽  
Natural Killer T

Primary Central Nervous System Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type Colliding with Meningioma

2018 ◽  
Vol 120 ◽  
pp. 17-26 ◽  
Author(s):  
Jiaqi Yan ◽  
Weiping Liu ◽  
Xichuan Wang ◽  
Sha Zhao ◽  
Limin Gao ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Killer T Cell ◽  
Natural Killer T

Orbital and Central Nervous System Extension of Nasal Natural Killer/T-Cell Lymphoma

2014 ◽  
Vol 30 (1) ◽  
pp. 20-23 ◽  
Author(s):  
Antonio A. V. Cruz ◽  
Fabiana C. P. Valera ◽  
Lucas Carenzi ◽  
Fernando Chahud ◽  
Gyl E. Barros ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Natural Killer T Cell ◽  
System Extension ◽  
Killer T Cell ◽  
Natural Killer T

Primary central nervous system natural killer/T-cell lymphoma: An atypical case of chronic meningitis

2017 ◽  
Vol 44 (3) ◽  
pp. 228-230 ◽  
Author(s):  
Lucas Alessandro ◽  
Federico Carpani ◽  
Naomi Arakaki ◽  
Diego Kaski ◽  
Hernan Chaves
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Chronic Meningitis ◽  
Atypical Case ◽  
Natural Killer T Cell ◽  
Killer T Cell

scholarly journals Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Huiqiang Huang ◽  
Jun Zhu ◽  
Ming Yao ◽  
Tae Min Kim ◽  
Dok Hyun Yoon ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Phase 2 ◽  
Nasal Type ◽  
Natural Killer T Cell ◽  
Phase 2 Study ◽  
Duration Of Response ◽  
Killer T Cell

Abstract Background Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a single-patient case report. We present data from the primary analysis of a phase 2 study of daratumumab monotherapy in relapsed or refractory (R/R) NKTCL. Methods This phase 2 study with Simon’s two-stage design evaluated daratumumab in patients with histologically confirmed extranodal NKTCL, nasal type, per WHO classification that was refractory to or relapsed after ≥ 1 line of chemotherapy, who were not candidates for other treatment modalities. All patients received daratumumab 16 mg/kg intravenously once weekly for Cycles 1 and 2, every other week for Cycles 3 through 6, and every 4 weeks thereafter until progression or unacceptable toxicity; all cycles were 28 days. The primary end point was objective response rate (ORR) based on blinded independent central review per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin Lymphoma (Lugano classification). Results In total, 32 Asian patients received daratumumab. The ORR was 25.0% (95% confidence interval [CI] 11.5–43.4); all 8 responders had a partial response; and the median duration of response was 55.0 days (95% CI 29–339). At 10.2 months of median follow-up, median progression-free survival (PFS) was 53.0 days (95% CI 43–106); the 4-month PFS rate was 13.0%. Median overall survival (OS) was 141.0 days (95% CI 94–438); the 6-month OS rate was 42.9%. Nineteen (59.4%) patients had grade 3/4 treatment-emergent adverse events (TEAEs); the most common was thrombocytopenia (25.0%; n = 8). TEAEs leading to death occurred in 4 patients (death, respiratory failure, septic shock, and pneumonia); all were unrelated to daratumumab. Conclusions In patients with R/R NKTCL, daratumumab monotherapy was well tolerated with no new safety concerns and achieved an ORR of 25.0%. However, no patients achieved complete response, and duration of response was short. Trial registration ClinicalTrials.gov, NCT02927925. Registered 7 October 2016.

Sign in / Sign up

Export Citation Format

Share Document